. . . that's a little harsh, cc . . . but it could certainly provide arna with an added excuse for continued lackluster performance . . .
. . . "FDA will Adjust the PDUFA Date by One Day Based on Revised Calendar Calculation -
SAN DIEGO, June 2, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced that the United States Food and Drug Administration (FDA) has informed the Company that the FDA intends to reassign the Prescription Drug User Fee Act (PDUFA) action date for the NB32 New Drug Application to June 11, 2014, one day beyond the original assignment. The FDA noted that due to an inadvertent administrative error, the Agency had miscalculated the originally assigned PDUFA date." . . .
. . . until the June 10 PDUFA date . . . unless, of course, there's an early announcement . . . that would be good, right, since areniacs already know it'll be rejected? . . . how much should I expect my arna/belphlop shares to rise as a result? . . .
. . . until the June 10 PDUFA date . . . then again, maybe there'll be an early decision . . . just sayin' . . .
. . . wrong as usual, b0 . . . OREXIGEN THERAPEUTICS, INC. filed this Form 10-K on 03/13/2014 . . . "Under the terms of the collaboration agreement, we received an upfront cash payment of $50 million from Takeda, and we are eligible to receive additional payments of over $1 billion upon achieving certain anniversary, regulatory and sales-based milestones, including $100 million that can be achieved between regulatory approval and the first commercial sale of NB32 in the United States, Canada and Mexico and $45 million in anniversary milestones." . . .
. . . "Lops Off 25% Market Cap" . . . really? . . . according to Google Finance (for the period ended May 30, 2014), Takeda's market cap stood at $35.85 billion and its share price (TKPYY) was $22.66, down 9.7% from its 52 week high of $25.09 . . . eisai (ESALY), for the same period, had a market cap of just $11.67 billion and a closing share price of $40.91, down 7.7% from its 52-week high of $44.31 . . . if you really don't understand market cap, ls, let me know and I'll try to walk you through it . . . good luck . . .
. . . what's to explain, gc . . . Takeda is obviously in good standing with the FDA . . . do you think otherwise? . . .
. . . ok, ah . . . I'm going to take that as a "yes" -- that you believe penny-ante retail pumpers on message boards are the key to sustained share price appreciation . . . maybe that's the unique edge that's delivered that 22,000% gain you're so proud of . . . continued good luck . . . with that . . .
. . . so am I to infer, ah, that you believe penny-ante retail pumpers on message boards are the key to sustained share price appreciation? . . . a simple yes or no would do . . . thanks . . .
. . . thanks, mn . . . the point is that -- contrary to the prevailing areniac fantasy here -- Takeda does not appear to be a liability to OREX or Contrave, as it is obviously not persona non grata with the FDA . . . capiche? . . . and "hipster"? . . . how old are you? . . .
. . . so you really do think that there's a correlation between the number of posts on a stock message board and the price of an equity? . . . also, ah, how old are you? . . . thanks . . .